117 related articles for article (PubMed ID: 33961943)
1. Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.
Ulander L; Tolppanen H; Hartman O; Rissanen TT; Paakkanen R; Kuusisto J; Anttonen O; Nieminen T; Yrjölä J; Ryysy R; Drews T; Utriainen S; Karjalainen P; Anttila I; Nurmi K; Silventoinen K; Koskinen M; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Int J Cardiol; 2021 Aug; 337():21-27. PubMed ID: 33961943
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Hartman O; Kovanen PT; Lehtonen J; Eklund KK; Sinisalo J
Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):92-97. PubMed ID: 28025216
[TBL] [Abstract][Full Text] [Related]
3. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Kleveland O; Kunszt G; Bratlie M; Ueland T; Broch K; Holte E; Michelsen AE; Bendz B; Amundsen BH; Espevik T; Aakhus S; Damås JK; Aukrust P; Wiseth R; Gullestad L
Eur Heart J; 2016 Aug; 37(30):2406-13. PubMed ID: 27161611
[TBL] [Abstract][Full Text] [Related]
4. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).
Abbate A; Kontos MC; Grizzard JD; Biondi-Zoccai GG; Van Tassell BW; Robati R; Roach LM; Arena RA; Roberts CS; Varma A; Gelwix CC; Salloum FN; Hastillo A; Dinarello CA; Vetrovec GW;
Am J Cardiol; 2010 May; 105(10):1371-1377.e1. PubMed ID: 20451681
[TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial.
Jaxa-Chamiec T; Bednarz B; Drozdowska D; Gessek J; Gniot J; Janik K; Kawka-Urbanek T; Maciejewski P; Ogórek M; Szpajer M;
Kardiol Pol; 2005 Apr; 62(4):344-50. PubMed ID: 16059992
[TBL] [Abstract][Full Text] [Related]
8. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
Hennessy T; Soh L; Bowman M; Kurup R; Schultz C; Patel S; Hillis GS
Am Heart J; 2019 Sep; 215():62-69. PubMed ID: 31284074
[TBL] [Abstract][Full Text] [Related]
9. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial.
Ripa RS; Jørgensen E; Wang Y; Thune JJ; Nilsson JC; Søndergaard L; Johnsen HE; Køber L; Grande P; Kastrup J
Circulation; 2006 Apr; 113(16):1983-92. PubMed ID: 16531621
[TBL] [Abstract][Full Text] [Related]
10. Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.
Jabbar A; Ingoe L; Junejo S; Carey P; Addison C; Thomas H; Parikh JD; Austin D; Hollingsworth KG; Stocken DD; Pearce SHS; Greenwood JP; Zaman A; Razvi S
JAMA; 2020 Jul; 324(3):249-258. PubMed ID: 32692386
[TBL] [Abstract][Full Text] [Related]
11. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]).
Pasupathy S; Tavella R; Grover S; Raman B; Procter NEK; Du YT; Mahadavan G; Stafford I; Heresztyn T; Holmes A; Zeitz C; Arstall M; Selvanayagam J; Horowitz JD; Beltrame JF
Circulation; 2017 Sep; 136(10):894-903. PubMed ID: 28634219
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction.
Steg PG; Grollier G; Gallay P; Morice M; Karrillon GJ; Benamer H; Kempf C; Laperche T; Arnaud P; Sellier P; Bourguignon C; Harpey C;
Int J Cardiol; 2001 Feb; 77(2-3):263-73. PubMed ID: 11182191
[TBL] [Abstract][Full Text] [Related]
13. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Tardif JC; Kouz S; Waters DD; Bertrand OF; Diaz R; Maggioni AP; Pinto FJ; Ibrahim R; Gamra H; Kiwan GS; Berry C; López-Sendón J; Ostadal P; Koenig W; Angoulvant D; Grégoire JC; Lavoie MA; Dubé MP; Rhainds D; Provencher M; Blondeau L; Orfanos A; L'Allier PL; Guertin MC; Roubille F
N Engl J Med; 2019 Dec; 381(26):2497-2505. PubMed ID: 31733140
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY β-blocker administration before primary PCI in patients with ST-elevation myocardial infarction trial.
Roolvink V; Rasoul S; Ottervanger JP; Dambrink JH; Lipsic E; van der Horst IC; de Smet B; Kedhi E; Marcel Gosselink AT; Piek JJ; Sanchez-Brunete V; Ibanez B; Fuster V; Van't Hof AW;
Am Heart J; 2014 Nov; 168(5):661-6. PubMed ID: 25440793
[TBL] [Abstract][Full Text] [Related]
16. The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction.
Ulander L; Simonen P; Tolppanen H; Hartman O; Rissanen TT; Eklund KK; Kalaoja M; Kurkela M; Neuvonen M; Niemi M; Backman JT; Gylling H; Sinisalo J;
Atheroscler Plus; 2023 Sep; 53():26-32. PubMed ID: 37448694
[TBL] [Abstract][Full Text] [Related]
17. China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.
Xu Y; Li X; Zhang H; Wu Y; Zhang J; Li J; Dou K; Yan H; You S; Yang Y; Liang Y; Xu L; Gao X; Liu C; Dong Q; Zhang W; Song G; Zhang T; Jiang L; Chen G; Tang R; Jin C; Yang J; Yao C; Xian Y; Peterson ED; Gao R; Yang Y
Am Heart J; 2020 Sep; 227():47-55. PubMed ID: 32679281
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
[TBL] [Abstract][Full Text] [Related]
19. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Wallentin L; Wilcox RG; Weaver WD; Emanuelsson H; Goodvin A; Nyström P; Bylock A;
Lancet; 2003 Sep; 362(9386):789-97. PubMed ID: 13678873
[TBL] [Abstract][Full Text] [Related]
20. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
Antman EM
Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
